We conducted a prospective, randomized clinical trial among liver transplant patients to assess the efficacy and safety of weekly sulfadoxine/pyrimethamine compared with daily trimethoprimsulfamethoxazole in the prevention of Pneumocystis carinii pneumonia. The studied drugs were given during 6 months after transplantation. One hundred twenty patients were included. None of the 60 patients receiving weekly sulfadoxine/pyrimethamine developed Pneumocystis carinii pneumonia, whereas two cases (3%) developed among the 60 patients who received trimethoprimsulfamethoxazole. For both patients, the studied medication had been discontinued several weeks earlier because of adverse effects. No differences were observed in the incidence of adverse effects. We conclude that weekly sulfadoxine/pyrimethamine is as effective and safe as is daily trimethoprim-sulfamethoxazole in the prophylaxis of Pneumocystis carinii pneumonia after liver transplantation.
Pneumocystis carinii pneumonia (PCP) is a common opportunistic infection in the setting of liver transplantation. Its incidence in the absence of prophylaxis has been shown to be ϳ3%-11% in the first 6 months after transplantation and can be even higher in the small group of patients with chronic rejection or who are treated with additional immunosuppressive therapy [1] [2] [3] [4] [5] [6] . PCP is clearly an infection to be prevented rather than treated. The prophylactic drug most commonly used is trimethoprim-sulfamethoxazole, and it has become a part of the standard care at many transplant centers [7] [8] [9] [10] [11] [12] [13] .
See editorial response by Gaut and Daar on pages 784 -6.
In contrast with the quantity of experience accumulated with trimethoprim-sulfamethoxazole prophylaxis, the effectiveness of alternative prophylactic strategies, including weekly regimens, has not been studied in persons without HIV infection. In an attempt to reduce daily medication, and taking into account the safety and efficacy of weekly sulfadoxine/pyrimethamine that some authors have observed for HIV-infected patients [14] , we thought that a prospective, randomized trial to determine the efficacy and safety of weekly sulfadoxine/pyrimethamine was justified.
Patients and Methods
Patient population. Patients were eligible for this trial if they were Ͼ18 years old and had received a liver allograft at our institution. Patients were excluded if they had taken sulfonamides, other inhibitors of folic acid metabolism, or clindamycin within 6 months of the study.
Study protocol. After the patients had given informed consent, block randomization was done for every 10 patients. One group received weekly prophylaxis with 500 mg of sulfadoxine/25 mg of pyrimethamine (Fansidar; Roche, Basel, Switzerland). The control group received daily prophylaxis with 480 mg of trimethoprim-sulfamethoxazole (Septrim; GlaxoWellcome, Madrid). The first dose was administered when the patient was able to take oral medication, and never after day 7 after transplantation. When oral medication was not possible, the drug was administered by nasogastric tube. We planned to give prophylaxis during the first 6 months after transplantation. To prevent bone marrow suppression, folinic acid supplementation was used.
The patients' tolerance of prophylactic therapy and the presence of symptoms and signs of PCP were monitored weekly during the first 4 weeks, at week 8, and at month 3. After month 3, the patient was evaluated only when clinically indicated. The evaluation included history, physical examination, laboratory tests (complete blood cell count and differential, platelet counts, measurement of electrolytes, aspartate and alanine aminotransferases, alkaline phosphatase, total bilirubin, and cyclosporine levels, and renal function and coagulation tests), and chest radiograph. Induced sputum was also obtained and P. ca-rinii was identified by means of a monoclonal antibody. Leukopenia was defined as Ͻ3 ϫ 10 9 leukocytes/L and thrombocytopenia as Ͻ100 ϫ 10 9 platelets/L. Maintenance immunosuppression consisted of standard triple therapy with cyclosporine, steroids, and azathioprine. Rejection episodes were treated with three doses of 1 g of methylprednisolone and/or an increase in oral prednisone that was reduced to the baseline in 5-7 days. Rejection episodes resistant to steroids were treated with OKT3 monoclonal antibody (5 mg/d for 7-10 days).
All patients received prophylaxis with high-dose acyclovir to prevent cytomegalovirus infection and disease. Cytomegalovirus infection was defined as isolation of the virus either from blood or during a biopsy. Cytomegalovirus disease was defined as culture or histological evidence of cytomegalovirus infection accompanied by consistent symptoms. Viral syndrome was defined as persistent fever and leukopenia, with or without anemia and thrombocytopenia, that could not be attributed to other causes in a patient with evidence of infection by culture. Organ disease was defined as symptomatic dysfunction with histological evidence of infection (definitive diagnosis) or isolation of virus from culture of a biopsy specimen without histological evidence (probable diagnosis). When evidence of dysfunction of two or more noncontiguous organs was demonstrated, the infection was considered disseminated.
PCP was diagnosed if the Pneumocystis organism was found in fluid obtained by bronchoalveolar lavage or in induced sputum. If PCP developed, the patient was withdrawn from the trial.
Statistical analysis. All patients who were randomized were included in the analysis according to the intention to treat with either trimethoprim-sulfamethoxazole or sulfadoxine/ pyrimethamine. Statistical analysis was performed with 2 test for qualitative data and Student's t test for quantitative data. The difference in the survival was calculated with the log-rank test. All P values were two-sided.
Results
One hundred twenty-five patients were included in the trial, but five patients were lost because of early death or noncompliance. At the end of the study, a total of 120 patients (60 patients in each group) were analyzed (table 1). Results are reported for all patients enrolled in the study (intention-to-treat analysis). The trimethoprim-sulfamethoxazole and sulfadoxine/pyrimethamine groups were well matched with regard to the number of patients, age, sex, underlying liver disease, pretransplant WBC count, pretransplant creatinine level, and cytomegalovirus status. Groups were also well matched regarding posttransplant parameters including surgical time, the number of days in the intensive care unit, the number of days of intubation, and the number of days receiving nonprophylactic antibiotics. The incidence of acute rejection and the use of steroids or OKT3 did not differ between groups.
Clinical outcome of prophylaxis. Overall, there was no difference in the global incidence of infection (table 2) . No episode of PCP was observed in the sulfadoxine/pyrimethamine group. In contrast, two patients (3%) in the trimethoprim-sulfamethoxazole group developed PCP. The scarce number of patients prevented observation of significant differences. In both patients, the administration of trimethoprim-sulfamethoxazole had been discontinued 4 and 6 weeks earlier because of leukopenia. They had not received an alternative prophylactic regimen. All patients with PCP recovered after treatment with trimethoprim-sulfamethoxazole given iv. There was no difference in the incidence of cytomegalovirus infection and disease (table 2) .
Adverse events and abnormal laboratory values. Eleven patients receiving trimethoprim-sulfamethoxazole (18%) and 10 patients receiving sulfadoxine/pyrimethamine (17%) had side effects (table 3) . Three patients in the trimethoprimsulfamethoxazole group (5%) and four patients in the sulfadoxine/pyrimethamine group (7%) developed a progressive increase in liver enzymes. The liver disfunction improved when the study drug was discontinued for one patient of the trimethoprim-sulfamethoxazole group and for two patients of the sulfadoxine/pyrimethamine group. Although a trend toward higher incidence of leukopenia (Ͻ3 ϫ 10 9 leukocytes/L) was observed in the trimethoprimsulfamethoxazole group, the difference was not significant (table 3) . When an episode of leukopenia was observed, the first step of our policy was to reduce the dose of azathioprine or even discontinue the drug. This permitted us to control four episodes in the trimethoprim-sulfamethoxazole group and two in the sulfadoxine/pyrimethamine group. In the remaining patients of both groups, the prophylactic drug was discontinued, and in all patients, the episode of leukopenia was resolved.
Mild gastrointestinal intolerance was reported in two patients (3%) of both groups (table 3). Discontinuation of therapy was not necessary.
Mortality. Mortality was similar in both groups after 1 year of follow-up. Thirteen patients (22%) died in the trimethoprimsulfamethoxazole group for the following reasons: bacterial infection (6), hepatitis virus reinfection (4), invasive aspergillosis (2), and cerebral hemorrhage (1). Twelve patients (20%) died in the sulfadoxine/pyrimethamine group as follows: bacterial infection (8) , invasive aspergillosis (1), and hepatitis virus reinfection (3).
Discussion
Primary PCP prophylaxis with daily high-dose trimethoprim-sulfamethoxazole (one double-strength tablet once or twice daily) and with intermittent regimens (one doublestrength tablet b.i.d. 3 days/week) is highly effective for transplant patients. Recently, the effectiveness of daily low-dose trimethoprim-sulfamethoxazole (one single-strength tablet once daily) has been demonstrated [12, 13] . On the basis of these studies, daily low-dose trimethoprim-sulfamethoxazole became the reference standard of PCP prophylaxis in our liver transplantation program.
The experience accumulated with trimethoprim-sulfamethoxazole prophylaxis in transplantation contrasts with the scarce data regarding alternative regimens. A number of other drugs have been proposed as prophylactic agents, but clinical experience is limited [15] . Pyrimethamine/sulfadoxine is an inexpensive longer-acting antipaludic agent that can be easily administered weekly. Concern about this agent is derived from occasional episodes of severe hepatitis and Stevens-Johnson syndrome among patients taking medication for malaria prophylaxis [16] . Cutaneous reactions, including toxic epidemic necrolysis, have been observed among patients infected with HIV [17] [18] [19] [20] [21] [22] . All of these observations contrast with the experience recently summarized by Jurado et al. [14] . In that study, 73 HIV-infected patients with Ͻ200 CD4 cells/mm 3 , who had received a minimum of a 3-month course of prophylaxis with weekly pyrimethamine/sulfadoxine (25 mg/500 mg), were studied. No patients in the primary prophylaxis group (56 patients) developed PCP. Of the 17 patients who had previously experienced PCP, only 2 patients relapsed. The treatment was well tolerated, and hepatitis, severe skin reactions, or leukopenia was not observed.
On the basis of the previous experience, we decided to compare weekly pyrimethamine/sulfadoxine with our reference standard (daily low-dose trimethoprim-sulfamethoxazole). Our results indicate that weekly pyrimethamine/sulfadoxine is safe and effective in preventing PCP in liver transplant recipients. None of the patients treated with weekly pyrimethamine/sulfadoxine developed pneumocystosis. The efficacy of trimethoprimsulfamethoxazole prophylaxis was also high, because the drug had been discontinued weeks earlier for the two patients with PCP. These two cases indicate that an alternative regimen is immediately needed when any prophylactic regimen is stopped. Inhaled or iv pentamidine could be the alternative regimen.
The efficacy of a prophylactic drug can be limited by the side effects. The data from our study do not suggest any difference in tolerance between the regimens. The observed side effects were similar in both groups: leukopenia, digestive intolerance, and increases in liver function test indicators. The potential hepatotoxicity of a drug always causes concern when it is used NOTE. Data are no. (%). No differences were statistically significant (P .05). Definitions: leukopenia, Ͻ3 ϫ 10 9 leukocytes/L; thrombocytopenia, Ͻ100 ϫ 10 9 platelets/L; hepatitis, evidence of mononuclear cell infiltration of the parenchyma and portal tracts in a liver biopsy sample with or without variable degrees of other changes. All thrombocytopenic patients were leukopenic as well.
to treat a liver transplant patient, in particular when severe episodes of hepatitis have been described with the same drug but in another indication. The incidence of hepatotoxicity was similar in both groups. Although the prophylactic treatment could be the cause of the abnormalities observed in liver function tests, the patients were treated with other potential hepatotoxic drugs, such as fluconazole, at the same time. It is difficult to know the contribution of each drug to liver toxicity. There was no difference in the incidence of leukopenia. The benefits of the prophylactic treatment were not limited by leukopenia. Mild digestive intolerance was observed for two patients of each group, but they responded to symptomatic medication. Nevertheless, vomiting can limit the absorption of the drug. It can be of particular importance for patients treated with weekly regimens, among whom PCP can develop when blood levels decrease under the therapeutic range.
In conclusion, weekly sulfadoxine/pyrimethamine was effective and well tolerated in preventing PCP among liver transplant recipients. From the data derived from the trimethoprim-sulfamethoxazole group, it can be inferred that the risk of PCP after the prophylactic drug is stopped is very high. In this case, a second-line agent should be introduced.
